临床表现 临床表现
Barbara L Fischer1, Carol A Van Hulle2, Derek L Norton3,4
1Department of Neurology University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
轻度行为障碍 (MBI) 影响认知能力下降,特别是在不同的人群中. 百叶状物度,即粉样蛋白-PET的度量,可能表明与MBI和认知衰退相关的早期大脑变化.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 轻度行为障碍 (MBI) 与认知衰退之间的联系已得到认可,但潜在的机制,特别是在多样化的人口中,需要进一步阐明.
- 这项研究调查了MBI,认知功能和白人和非裔美国成年人的各种生物标志物之间的相互作用.
- 数据来自非洲裔美国人在中年抗击阿尔茨海默病 (AA-FAIM) 研究和威斯康星州阿尔茨海默病预防注册表 (WRAP) 的数据.
研究的目的:
- 探索MBI,认知轨迹和六个生物标志物之间的关系在种族多样化的队列中.
- 为了确定MBI是否会影响随着时间的推移生物标志物和认知衰退之间的关联.
- 评估MBI与临床痴呆时间评级 (CDR) >0.0的关联.
主要方法:
- 没有痴呆症的参与者接受了评估,包括神经精神病学库存问卷 (NPI-Q) 和生物标志物分析 (海马体积,粉样蛋白-PET,血生物标志物:ptau217,Aβ42/40,GFAP,NfL).
- 混合效应线性模型检查了MBI对生物标志物-认知关联随时间推移的影响.
- 考克斯的比例危险模型评估了MBI与CDR>0.0的时间之间的关联.
主要成果:
- 在MBI和大多数关于认知衰退的生物标志物 (HPV,ptau217,Aβ42/40,NfL,GFAP) 之间没有发现显著的三向相互作用.
- 患有MBI的个体在所有认知指标上表现出加速下降.
- 在GFAP和百叶状物模型中,更高的百叶状物值 (amyloid-PET) 与更快的记忆衰退显著相关,并且基线MBI与CDR>0的时间相关.
结论:
- 研究结果表明,MBI可能会改变特定生物标志物和认知衰退之间的关系,特别明显的是百叶状物度.
- 百叶状物度,一个标准化的粉样蛋白-PET测量,显示承诺作为一个敏感的指标,早期,稳定的大脑变化与MBI在不同的人群中相关.
- 需要进一步的研究来证实这些初步发现,并了解涉及到的精确机制.
相关概念视频
Chronic Kidney Disease II: Clinical Manifestations
520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
Coronary Artery Disease III: Clinical Manifestations
299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
Endocarditis II: Clinical Features of Infective Endocarditis
364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
Heart Failure III: Clinical Manifestations
436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
Gastroesophageal Reflux Disease II: Clinical Features and Management
652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437


